Sumary of Pfizer’s coronavirus vaccine: Here’s what experts are saying about the new data:
- Pfizer released an early snapshot of its Phase 3 trials for its coronavirus vaccine on Monday, and said the results look promising with data suggesting it 90 per cent effective at preventing the virus..
- 2:30 Mink COVID-19 outbreaks raises concerns over new strain Mink COVID-19 outbreaks raises concerns over new strain What does the Phase 3 COVID-19 data say?.
- Monday interim analysis, from an independent data monitoring board, looked at 94 confirmed cases of COVID-19 among the volunteers who had either received two doses of the vaccine or a placebo..
- began on July 27 and has enrolled 43,538 participants — 38,955 of whom have received a second dose of the vaccine candidate as of Nov..
- According to the findings, the trial found that fewer than 10 per cent of infections were in participants who had been given the vaccine, a strong signal of efficacy..
- Pfizer said that the vaccine provided protection seven days after the second dose and 28 days after the initial dose of the vaccine..
- Vaccine Hesitancy Infection control epidemiologist Colin Furness, an assistant professor at the University of Toronto, said there is still a lot of data that needs to be reviewed..
- He said he would like to know what the experience was for participants who received the COVID-19 vaccine and still got the virus..
- “All of this data should be released, such as the demographics, who got sick, and obviously what the side effects of the vaccine are..
- could lead to rushing a vaccine, Furness said, companies like Pfizer are aware that “public trust may be shaky.”…